ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
View original at finance.yahoo.comWhat we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Treatment had a favorable safety profile: most treatment-related adverse events were Grade 1 or 2 localized bladder symptoms, Grade 3 occurred in 4% of patients, and no Grade 4 or 5 treatment-related events were reported.
60% confidenceANKTIVA plus BCG showed a 71% complete response rate, median CR duration of 26.6 months with responses beyond 53 months, and more than half of responders in the FDA-reviewed population maintained CR beyond 45 months.
60% confidenceQUILT-3.032 is one of the longest follow-up data sets in BCG-unresponsive NMIBC to date and supports the durability of ANKTIVA's mechanism of action in generating sustained immune responses; findings suggest potential for prolonged disease control and avoiding or delaying radical cystectomy for some patients.
60% confidencePeer-reviewed results add to the growing body of evidence supporting ANKTIVA plus BCG and highlight potential for sustained disease control and cystectomy avoidance for patients with limited options.
60% confidence